WO2022078524 - SPECIFIC CONJUGATION OF AN ANTIBODY
National phase entry:
Publication Number
WO/2022/078524
Publication Date
21.04.2022
International Application No.
PCT/CN2021/128453
International Filing Date
03.11.2021
Title **
[English]
SPECIFIC CONJUGATION OF AN ANTIBODY
[French]
CONJUGAISON SPÉCIFIQUE D'UN ANTICORPS
Applicants **
HANGZHOU DAC BIOTECH CO., LTD.
1st
Building 12, No. 260 Sixth Street
Zhengtaizhongzi Sci &Tech Park, HEDA
Hangzhou, Zhejiang 310018, CN
Inventors
ZHAO, Robert
1st
7 Loring Road
Lexington, Massachusetts 02421, US
YANG, Qingliang
4th Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
LIU, Xiaolei
3rd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
ZHANG, Lingli
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
HUANG, Yuanyuan
4th Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
LI, Wenjun
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
YE, Hangbo
4th Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
WANG, Juan
1st Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
GUO, Huihui
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
ZHOU, You
2nd Floor
Building 12, 260 Sixth Street
Hangzhou, Zhejiang 310018, CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 8845 | |
| EPO | Filing, Examination | 20439 | |
| Japan | Filing | 502 | |
| South Korea | Filing | 450 | |
| USA | Filing, Examination | 5060 |
Total: 35296 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein is a process for preparing a homogeneous conjugate of an antibody or antibody-like protein via linkage of cysteine sites between heavy-light chains in the IgG antibody or antibody-like protein. It also relates to methods of making the conjugates in a specific manner comprising either generation of specific thiols of an antibody or antibody-like protein agent, followed by reaction with drug/linker complexes, or generation of specific thiols of an antibody or antibody-like protein agent and conjugation of a synthetic linker-drug assembly with the thiols simultaneously in one pot reaction, to provide conjugates with over 75%, in most cases more than 80% of payloads linked at the specific cysteine sites between heavy-light chains of the IgG antibody or antibody-like protein. It also relates to methods of using the homogeneous conjugate in targeted prophylaxis or treatment of cancer, infection and immunological disorders.[French]
L'invention concerne un procédé de préparation d'un conjugué homogène d'un anticorps ou d'une protéine de type anticorps par liaison de sites de cystéine entre des chaînes légères-lourdes dans l'anticorps IgG ou la protéine de type anticorps. La présente invention concerne également des procédés de fabrication des conjugués d'une manière spécifique comprenant soit la génération de thiols spécifiques d'un anticorps ou d'un agent de protéine de type anticorps, suivie d'une réaction avec des complexes médicament/lieur, soit la génération de thiols spécifiques d'un anticorps ou d'un agent de protéine de type anticorps et la conjugaison d'un ensemble lieur synthétique-médicament avec les thiols simultanément dans une réaction monotope, pour obtenir des conjugués avec plus de 75 %, dans la plupart des cas plus de 80 % de charges utiles liées au niveau des sites de cystéine spécifiques entre des chaînes légères-lourdes de l'anticorps IgG ou de la protéine de type anticorps. L'invention concerne également des procédés d'utilisation du conjugué homogène dans la prophylaxie ou le traitement ciblé du cancer, d'une infection et de troubles immunologiques.